Equity Overview
Price & Market Data
Price: $16.74
Daily Change: +$0.47 / 2.81%
Daily Range: $16.41 - $16.74
Market Cap: $1,798,436,096
Daily Volume: 908
Performance Metrics
1 Week: 27.51%
1 Month: 17.47%
3 Months: 42.84%
6 Months: 21.24%
1 Year: 370.2%
YTD: 34.69%
Company Details
Employees: 136
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.